Skip to Content
Merck
  • UVRAG Promotes Tumor Progression through Regulating SP1 in Colorectal Cancer.

UVRAG Promotes Tumor Progression through Regulating SP1 in Colorectal Cancer.

Cancers (2023-05-13)
Mengyuan Shi, Guo An, Nan Chen, Jinying Jia, Xinxin Cui, Tiancheng Zhan, Dengbo Ji
ABSTRACT

Colorectal cancer (CRC) is the third most common type of cancer. The ultraviolet radiation resistance-associated gene (UVRAG) plays a role in autophagy and has been implicated in tumor progression and prognosis. However, the role of UVRAG expression in CRC has remained elusive. In this study, the prognosis was analyzed via immunohistochemistry, and the genetic changes were compared between the high UVRAG expression group and the low UVRAG expression group using RNA sequencing (RNA-seq) and single-cell RNA-seq (scRNA-seq) data, and genetic changes were then identified by in vitro experiments. It was found that UVRAG could enhance tumor migration, drug resistance, and CC motif chemokine ligand 2 (CCL2) expression to recruit macrophages by upregulating SP1 expression, resulting in poor prognosis of CRC patients. In addition, UVRAG could upregulate the expression of programmed death-ligand 1 (PD-L1). In summary, the relationship between UVRAG expression and the prognosis of CRC patients as well as the potential mechanisms in CRC were explored, providing evidence for the treatment of CRC.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-PDCD1LG2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution